Kidney cancer recurrence can happen soon after surgery or, less often, many years later. The available figures show why recurrence estimates must be read in context: tumor size, stage, grade, histology, surgical margins, and the type of recurrence all change the outlook. The figures below focus mainly on renal cell carcinoma (RCC), especially clear cell RCC, and preserve each study’s measurement period and population.
Contents
- At-a-glance kidney cancer numbers
- When recurrence happens
- Where kidney cancer recurs
- Risk by tumor size and stage
- Late recurrence after five years
- Surgery, local recurrence, and margins
- Adjuvant treatment and recurrence-free survival
At-a-glance kidney cancer numbers
The National Cancer Institute’s Renal Cell Cancer Treatment PDQ estimated 80,980 new renal cell cancer cases in the United States in 2025 and 14,510 deaths. The same source reports that about 75% of patients survive five years, in part because many cancers are diagnosed while still localized. These are U.S. estimates for 2025, not recurrence rates for an individual patient.
The NCI also notes that late tumor recurrence, occurring many years after initial treatment, occasionally occurs in renal cell cancer. That observation is important when interpreting studies that report recurrence after five or even 10 years: a long disease-free interval lowers neither every patient’s risk to zero nor the need to understand the follow-up period used by a study.
Several studies use different outcomes. “Recurrence-free survival” or RFS describes the proportion without recurrence at a stated time. A recurrence count describes observed cases in a particular cohort. A hazard ratio compares relative event rates between groups or according to a variable; it is not itself a percentage chance for one person.
When recurrence happens
In the study titled Renal cell carcinoma: analysis of postoperative recurrence patterns, RCC usually recurred within two years after surgery. That is a pattern-level finding, not a guarantee that recurrence will occur in that window. The same study found higher recurrence among tumors at least 5 cm than among tumors smaller than 5 cm, among T3a/T3b tumors than T1 tumors, among stage III tumors than stage I tumors, and among nuclear grade 3 or 4 tumors than grade 1 or 2 tumors.
Longer follow-up shows why “early” and “late” recurrence should be separated. In Recurrence of renal cell carcinoma more than 5 years after nephrectomy, 57 patients had early recurrence within five years after nephrectomy, while 11 patients had delayed recurrence after five years. The study did not establish that these counts apply to all people treated for kidney cancer.
An organ-confined RCC study followed patients for a median of 59 months and reported 10-year RFS by tumor category:
| Tumor category | 10-year recurrence-free survival |
|---|---|
| T1a | 94.5% |
| T1b | 75.0% |
| T2 | 57.9% |
That study also reported the mean risk of recurrence after five years as 0.5% per year for T1a tumors, 3.0% per year for T1b tumors, and 3.2% per year for T2 tumors. These annual figures are study estimates for organ-confined disease; they should not be added together as though they were independent yearly probabilities.
Where kidney cancer recurs
Observed recurrence sites vary by cohort and study design. In Renal cell carcinoma: analysis of postoperative recurrence patterns, the reported counts were 29 lung recurrences, 13 bone recurrences, 7 nephrectomy-site recurrences, 6 brain recurrences, 5 liver recurrences, and 5 mediastinal lymph-node recurrences. The same study recorded 4 contralateral-kidney recurrences and 2 neck-muscle recurrences.
In the high-risk nonmetastatic study Patterns of Initial Metastatic Recurrence After Surgery for High-Risk Nonmetastatic Renal Cell Carcinoma, lung was the most common metastatic recurrence site: 144 of 270 cases, or 53.3%. Liver accounted for 54 of 270 cases, or 20.0%, and bone accounted for 48 of 270 cases, or 17.8%.
A time-dependent study, Time-dependent change in relapse sites of renal cell carcinoma after curative surgery, reported the following recurrence percentages for clear cell RCC:
| Recurrence site | Clear cell RCC recurrences |
|---|---|
| Lung | 46.6% |
| Bone | 17.9% |
| Liver | 7.6% |
| Lymph nodes | 6.5% |
The percentages come from that study’s clear cell RCC analysis and are not interchangeable with the counts from the postoperative-pattern study or the 270-case high-risk study. The time-dependent study reported no recurrence beyond five years after surgery for papillary RCC or chromophobe RCC, while clear cell carcinoma had 20 recurrence cases beyond 10 years.
Risk by tumor size and stage
Tumor size and stage repeatedly appear in the supplied recurrence research as markers associated with different outcomes. The postoperative-pattern study found higher recurrence for tumors at least 5 cm, for T3a/T3b tumors compared with T1 tumors, and for stage III tumors compared with stage I tumors. It also found higher recurrence for nuclear grade 3 or 4 than for grade 1 or 2.
The late-recurrence cohort Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma recorded 63 patients with late renal recurrence, representing 4.3% of the cohort. The median time to late renal recurrence was 9.3 years. In the same cohort, 172 patients developed late distant metastases, representing 11.8%, with a median time to late distant metastasis of 9.6 years.
In that cohort, increased tumor size had a hazard ratio of 1.12 for late renal tumor recurrence and 1.07 for late distant metastasis. Clear cell or collecting-duct histology had a hazard ratio of 3.76 for distant metastasis. The reported hazard ratios for distant metastasis by pathologic stage were 2.8 for pT1b, 4.5 for pT2a, 3.4 for pT2b, and 5.1 for pT3-pT4.
These hazard ratios describe associations within the study’s model. They do not mean that a pT3-pT4 tumor has a 5.1% recurrence risk, nor do they provide an individual prognosis without the rest of the clinical context.
Late recurrence after five years
The study Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis divided patients into four groups: 425 in the no-recurrence group, 138 with synchronous metastasis, 143 with early recurrence, and 41 with late recurrence. The group sizes show why late-recurrence percentages can look different across publications: researchers may define groups and eligibility differently.
The reported late recurrence findings also fit the broader NCI statement that renal cell cancer can occasionally recur many years after initial treatment. In the time-dependent relapse-site study, clear cell carcinoma had 20 recurrence cases beyond 10 years, whereas no recurrence beyond five years was reported for papillary or chromophobe RCC in that study. Histology and follow-up duration therefore matter when reading a “late recurrence” statistic.
Late recurrence does not always mean recurrence in the kidney. The late-recurrence cohort distinguished late renal recurrence from late distant metastasis: 63 patients had the former and 172 had the latter, with different median times. Those outcomes should not be combined into one percentage or treated as equivalent events.
Surgery, local recurrence, and margins
Local recurrence estimates depend on the procedure. Recurrent disease in renal cell carcinoma. “Local recurrence” after kidney-sparing and radical resection reported locally recurrent RCC at 0–10% after nephron-sparing surgery, 2.5–4% after thermoablative interventions, and 2–3% after radical nephrectomy. These are reported ranges from that review, not a direct head-to-head prediction for every surgical setting.
Studies of partial nephrectomy also reported differing outcomes by surgical margin status. Predictors and oncological outcomes following positive surgical margins at partial nephrectomy reported five-year freedom from local recurrence of 97% for negative margins and 98% for positive margins. In contrast, The Prognostic Impact of the Surgical Margin in Renal Cell Carcinoma Treated with Partial Nephrectomy: A Multi-Center Study reported five-year recurrence-free survival of 80% with positive surgical margins and 93% with negative margins.
The population-based study Prevalence and impact on survival of positive surgical margins in partial nephrectomy for renal cell carcinoma reported five-year disease-specific survival of 90.9% with positive margins and 91.9% with negative margins. Its five-year overall survival figures were 84.4% with positive margins and 88.6% with negative margins.
The differences among these reports do not prove that one number applies universally. They reflect different study populations, endpoints, follow-up methods, and definitions. “Freedom from local recurrence,” “recurrence-free survival,” disease-specific survival, and overall survival measure related but different outcomes.
Adjuvant treatment and recurrence-free survival
The NCI Renal Cell Cancer Treatment PDQ describes KEYNOTE-564, an adjuvant trial of pembrolizumab after nephrectomy. The trial enrolled 994 patients with clear cell RCC at high risk of recurrence. Eligibility included stage II disease with nuclear grade 4 or sarcomatoid differentiation, stage III disease or higher, regional lymph-node metastases, or M1 NED status.
At a median follow-up of 24 months, two-year disease-free survival was 77.3% with pembrolizumab versus 68.1% with placebo. The disease-free-survival hazard ratio was 0.68. At a median follow-up of 30 months, disease-free survival was 75.2% with pembrolizumab versus 65.5% with placebo, with a hazard ratio of 0.63.
The same NCI summary reported grade 3 or higher adverse events in 32% of pembrolizumab patients and serious adverse events in 20%. The most common high-grade adverse events were diarrhea and transaminitis, each at 2%. The most common serious adverse events were adrenal insufficiency, colitis, and diabetic ketoacidosis, each at 1%.
Only 36% of the 166 control-group patients in KEYNOTE-564 received immunotherapy at relapse. That detail matters when comparing the trial’s disease-free-survival results with later treatment experiences: post-recurrence therapy was not identical for every patient, and the trial’s figures describe its enrolled high-risk population rather than all kidney cancer survivors.